December 4, 2017. 

Hummingbird Bioscience, a preclinical -stage drug development company focused on novel cancer immuno-therapeutics, will present a poster “HMBD-004A, a Novel Anti-CD47xCD33 Bispecific Antibody Displays Potent Anti-Tumor Effects in Pre-Clinical Models of AML” at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta on 9th December.

HMBD-004A is a bispecific antibody targeting CD47 and CD33, developed using Hummingbird’s proprietary Rational Antibody Discovery platform.

CD47 is the “don’t-eat-me” signal, ubiquitously expressed on normal cells, and is over-expressed 5-10 fold on AML cells.  Anti-CD47 therapies have shown promising anti-tumor efficacy in both preclinical and clinical studies. However the widespread expression of CD47 decreases the bioavailability of anti-CD47 antibodies at the tumor, while the high expression of CD47 on red blood cells also presents a safety risk.  

Through simultaneous binding of CD33, which is significantly over-expressed on AML cells, HMBD-004A achieves increased specificity for tumor cells, while reducing the risk of cross-linking red blood cells. HMBD-004A has demonstrated excellent efficacy and safety in pre-clinical models.

The poster will be presented on Saturday, December 9, 2017, 5:30 PM-7:30 PM in Hall A2 of the Georgia World Congress Center.

In addition, Hummingbird has today announced that it has signed a Research Evaluation Agreement with Genmab to access the DuoBody® bispecific technology platform to further the development of HMBD-004A.

For further information please email CEO Piers Ingram: contact@hummingbirdbio.com  


About Hummingbird Bioscience

Hummingbird Bioscience is an innovative biotechnology company, harnessing the potential of integrative biology to discover and develop novel cancer immuno-therapeutics.  We are focused on taking projects from validated target to clinical proof of concept. Our data and model driven integrative biology approach provide an unprecedented ability to understand and manipulate the immune system – allowing us to 1) Identify the right targets and mechanisms 2) Generate best in class antibodies against these targets 3) Characterize the effect of our drug candidates on the tumor and immune system at a molecular and cellular level, to better predict clinical outcomes of our drugs.  We have compelling pre-clinical data for four potential first in class therapeutic programs focused on the most exciting targets in oncology.

About Genmab and its DuoBody® Platform

Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Genmab’s DuoBody platform is an innovative platform for the discovery and development of bispecific antibodies. DuoBody molecules are unique in combining the benefits of bispecificity with the strengths of conventional antibodies which allows DuoBody molecules to be administered and dosed as other antibody therapeutics. Genmab's DuoBody platform generates bispecific antibodies via a fast and broadly applicable process which is easily performed at standard bench, as well as commercial, manufacturing scale.

Sections

  • INVESTMENT BY DECHENG CAPITAL
  • HUMMINGBIRD BIOSCIENCE TO PRESENT DATA ON HMBD-004A AT THE 59TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING